Objectives: Tumor spread through air spaces (STAS) is a novel invasive pattern in lung adenocarcinoma (ADC). The effects of the combination of STAS and tumor size on survival have not been well studied.
Introduction
Surgical resection is the most effective treatment for early-stage lung adenocarcinoma (ADC). However, the 5-year postoperative recurrence rate reaches 30%. 1, 2 Tumor spread through air spaces (STAS) was listed as an additional invasive pattern of lung ADC in the WHO guidelines. 3, 4 STAS is defined as single cells, micropapillary clusters, or solid nests that are observed within air spaces in the surrounding lung parenchyma beyond the edge of the tumor. 5 Recently, several studies demonstrated clearly that STAS offers another convincing explanation for postoperative recurrence of ADC.
Although much effort has been made in searching for biomarkers that can aid in predicting the prognosis of patients with ADC, tumor size is an irreplaceable prognostic factor because of the significant difference in survival outcome observed with each centimeter of increase in tumor size. 11 Aside from estimating prognosis, tumor size also contributes to treatment decisions (postoperative chemotherapy) and serves as a common language when enrolling patients in clinical trials (lobectomy versus limited resection). 12, 13 However, the effects that the combination of STAS and tumor size have on survival have not yet been well studied. Thus, we performed a survival analysis using a large cohort of patients with resected lung ADC 3 cm or smaller (stage IA) to determine whether STAS could further stratify survival beyond stratification by tumor size.
Materials and Methods

Patient Selection
The institutional review board of Shanghai Pulmonary Hospital approved this study (institutional review board no. K17-004). From January 2009 to December 2010, 2665 patients with lung cancer underwent an operation at Shanghai Pulmonary Hospital. We reviewed their records and included 383 cases with ADC 3 cm or smaller (stage IA) and 161 cases with stage IB ADC in the study cohort. Patients were excluded from the study cohort if one of the following criteria was met: (1) receipt of neoadjuvant therapy, (2) presence of multiple primary lung cancers, (3) presence of ADC in situ or minimally invasive ADC, and (4) receipt of R1 resection (microscopic residual) or R2 resection (gross residual). R1 resection was defined as complete resection with no visible tumor but with microscopic cancer cells left behind, and R2 resection was defined as partial resection with visible tumor left behind. Characteristics of patients were retrospectively collected and sorted from electronic medical records. Outpatient clinic revisit records and telephone follow-up data were used to collect survival information. The end date of follow-up for the present study was December 31, 2016. Moreover, we also included a validation cohort (405 patients with ADC 3 cm [stage IA] and 136 patients with stage IB ADC) with the aforementioned criteria between January 2011 and March 2012.
Histopathologic Evaluation of STAS
The hematoxylin and eosin-stained slides of resected tumor specimens were evaluated microscopically by two pathologists (H. X. and L. Z.), who were blinded to the clinical characteristics and survival outcomes of patients.
Tumor STAS in lung ADC has been well defined in a previous study. 5 Briefly, STAS was defined as tumor cells observed within air spaces in the surrounding lung parenchyma beyond the edge of the main tumor. It was classified into three morphologic subtypes: (1) single cells ( Fig. 1A and B) ; (2) micropapillary clusters ( Fig. 1C and D); and (3) solid nests ( Fig. 1E and F) . Single cells were defined as discohesive single tumor cells within air spaces, micropapillary clusters as papillary structures without central fibrovascular cores within air spaces, and solid nests as solid collections of tumor cells filling air spaces. 5 Two pathologists (H. X. and L. Z.) classified STAS into single-cell, micropapillary cluster, or solid nest-predominant subtypes when a pattern was predominant within air spaces, even when minor components of other patterns could be observed. In the event of disagreement, a consensus was reached after discussion. We also adopted the methods described by Kadota et al. to distinguish STAS from alveolar macrophages and artifacts. 5 If making the distinction from macrophages was still difficult, immunohistochemistry for a tumor cell marker (thyroid transcription factor 1) and a macrophage marker (CD68) was performed.
In addition, the distance between the tumor margin and furthest STAS was measured with a ruler. Because of artifactual atelectasis during the processing of lung specimens, the number of alveolar spaces was also counted as another way of measuring distance between the tumor edge and the furthest STAS. 14 Tumors were classified into lepidic, acinar, papillary, micropapillary, or solid predominant subtypes when a pattern was predominant in the tumor (even if <50%). If disagreement occurred, discussion was necessary before reaching a consensus.
Histopathologic Evaluation of ADC
Statistical Analysis
Demographic and clinicopathologic data are presented as median (range) and number (percentage). Categorical variables were compared by Pearson's c 2 test, and numerical variables were compared by Student's t test. Recurrence-free survival (RFS) and overall survival (OS) were the outcomes of interest for survival analysis. RFS and OS were calculated by the KaplanMeier method and compared by the using log-rank test between patients with and those without STAS by tumor size. Furthermore, a Cox proportional hazards regression model was applied to adjust potential confounders to evaluate independent risk factors for RFS and OS.
In this study, a two-sided p value less than 0.05 was considered statistically significant. All analyses were performed with SPSS 22.0 software (IBM Corporation, Armonk, NY), and the survival curves were plotted using GraphPad Prism 7.0 software (GraphPad Software, San Diego, CA).
Results
Patient Clinicopathologic Characteristics
We identified 383 and 405 patients with ADCs 3 cm or smaller (stage IA) in the study and validation cohorts, respectively. The detailed clinicopathological characteristics are presented in Table 1 and Supplementary  Table 1 . In both cohorts, most of the included patients underwent lobectomy (in the study cohort, 95% had a lobectomy and 5% had a limited resection; in the validation cohort, 93% had a lobectomy and 7% had a limited resection). The acinar pattern was the most common predominant subtype of ADC (45% in the study cohort versus 39% in the validation cohort).
We also collected the clinical information on patients with stage IB ADC in the study cohort and validation cohort. Details are listed in Supplementary Table 2 .
Incidence and Features of STAS in ADCs 3 cm or Smaller
STAS was observed in 116 ADCs (30.3%) in the study cohort and 127 (31.4%) ADCs in the validation cohort. Figure 1 shows the representative images of STAS. STAS was more likely to be observed in male patients (study cohort: 35% versus 26% [p ¼ 0.043]; validation cohort: 42% versus 24% [p ¼ 0.01]) (see Table 1 and  Supplementary Table 1 ) and patients with high-grade histologic ADC (study cohort: 89% versus 11% with the lepidic subtype, 64% versus 36% with the acinar subtype, 60% versus 40% with the papillary subtype, 17% versus 83% with the micropapillary subtype, and 43% versus 57% with the solid subtype [p < 0.001]; validation cohort: 91% versus 9% with the lepidic subtype, 57% versus 43% with the acinar subtype, 66% versus 34% with the papillary subtype, 36% versus 64% with the micropapillary subtype, and 36% versus 64% with the solid subtype [p < 0.001]) (see Table 1 and Supplementary Table 1) .
The median distance between tumor surface and furthest STAS was microscopically measured with a ruler as 1 mm (range 0.3-6 mm) in the study cohort and 1.5 mm (range 0.3-8 mm) in the validation cohort ( Supplementary  Fig. 1A and C). In addition, the median number of alveolar spaces between the tumor surface and the furthest STAS was six (range 1-45) in the study cohort and seven (range 1-29) in the validation cohort ( Supplementary Fig. 1B  and D) . If the approximate alveolar size was assumed to be 0.3 mm, 5 the maximum estimated distance between STAS and the tumor edge was 1.35 cm in the study cohort and 0.87 cm in the validation cohort.
Correlation of Different Types of STAS with Predominant Pattern of ADC
When STAS was stratified by three morphologic subtypes, the study cohort included 19 cases of single-cell STAS (16%), 90 cases of micropapillary cluster STAS (78%), and seven cases of tumor nest STAS (6%), whereas the validation cohort included 11 cases of singlecell STAS (9%), 106 cases of micropapillary cluster STAS (83%), and 10 cases of tumor nest STAS (8%).
Supplementary Figure 2 shows that there was a statistical difference in the distribution of the three types of STAS according to the histologic pattern of ADC (study cohort, p ¼ 0.011; validation cohort, p < 0.001). Micropapillary cluster STAS was the most common type in all histologic patterns (study cohort: 73% in lepidic predonimant ADCs, 81% in acinar predonimant ADCs, 81% in papillary predonimant ADCs, 80% in micropapillary predonimant ADCs, and 58% in solid predonimant ADCs; validation cohort: 77% in lepidic predonimant ADCs, 91% in acinar predonimant ADCs, 90% in papillary predonimant ADCs, 86% in micropapillary predonimant ADCs, and 50% in solid predonimant ADCs). As to the other types of STAS, single-cell STAS was a common pattern in lepidic predominant ADC (27% in the study cohort and 23% in the validation cohort), whereas tumor nest STAS was a common pattern in solid predominant ADC (34% in the study cohort and 50% in the validation cohort).
Tumor STAS Affected Survival in ADC 3 cm or Smaller in the Study Cohort
Survival analysis of patients with ADC 3 cm or smaller showed that patients without STAS had a better RFS than those with STAS (hazard ratio [HR] ¼ 2.01, 95% confidence interval [CI]: 1.23-3.30, p ¼ 0.006) ( Fig. 2A) . Furthermore, similar RFS was observed in patients with ADC 3 cm or smaller with STAS present and in those with stage IB ADC (HR ¼ 1.42, 95% CI: 0.95-2.14, p ¼ 0.091) (see Fig. 2A ). This trend was also observed in the OS analysis ( 
Tumor STAS Affected Survival in ADCs Larger Than 2 to 3 cm but Not 2 cm or Smaller in the Study Cohort
We assessed the impact of STAS on survival by further stratifying patients by tumor size. Patients with ADCs 3 cm or smaller were divided into four groups according to tumor size ( 2 cm or >2-3 cm) and STAS status (presence or absence). Figure 3A and B shows that STAS slightly stratified the RFS (HR ¼ 1.83, 95% CI: 0.91-3.69, p ¼ 0.091) and OS (HR ¼ 2.19, 95% CI: 0.94-5.10, p ¼ 0.072) in patients with tumors 2 cm or smaller, but this trend did not reach statistical significance. However, a significant difference in RFS (HR ¼ 2.36, 95% CI: 1.16-4.80, p ¼ 0.017) and OS (HR ¼ 3.94, 95% CI: 1.80-8.63, p ¼ 0.001) was found between patients with tumors larger than 2 to 3 cm with and without STAS (Fig. 3C and D) .
Next, we examined whether patients with tumors 2 cm or smaller and larger than 2 to 3 cm with STAS had RFS and OS rates similar to those of patients with larger tumors. Log-rank tests indicated no significant difference in RFS (HR ¼ 0.96, 95% CI: 0.51-1.83, p ¼ 0.912) and OS (HR ¼ 0.90, 95% CI: 0.42-1.92, p ¼ 0.784) between patients with ADCs 2 cm or smaller with STAS present and those with ADCs larger than 2 to 3 cm with STAS absent (see Fig. 3A and B) . Tests also indicated no difference in RFS (HR ¼ 0.95, 95% CI: 0.55-1.64, p ¼ 0.842) and OS (HR ¼ 0.67, 95% CI: 0.36-1.24, p ¼ 0.205) between patients with ADCs larger than 2 to 3 cm with STAS present and those with stage IB ADC (see Fig. 3C and D) . Detailed results are presented in Table 3 .
Survival Analysis in the Validation Cohort
We also assessed the effects of the combination of STAS and tumor size on survival in a validation cohort. Similar results were obtained in the validation cohort when compared with those in the study cohort.
Among patients with ADCs 3 cm or smaller, the presence of STAS was associated with worse RFS (HR ¼ 2.29, 95% CI: 1.36-3.86, p ¼ 0.002) and OS (HR ¼ 2.31, 95% CI: 1.29-4.12, p ¼ 0.005) (Supplementary Fig. 3 ). Furthermore, there was no statistically significant difference in RFS (HR ¼ 1.52, 95% CI: 0.98-2.36, p ¼ 0.062) and OS (HR ¼ 1.54, 95% CI: 0.95-2.51, p ¼ 0.079) between patients with ADC 3 cm or smaller with STAS present and those with stage IB ADC (see Supplementary  Fig. 3 ). Multivariate analysis revealed STAS to be an independent risk factor for RFS (HR ¼ Fig. 4C and D) . Moreover, the unfavorable prognosis of patients with ADC larger than 2 to 3 cm with STAS present was comparable to that of patients with stage IB ADC (RFS: HR ¼ 1.00, 95% CI: 0.57-1.74, p ¼ 0.993; OS: HR ¼ 0.99, 95% CI: 0.54-1.83, p ¼ 0.982) (see Supplementary Fig. 4C and D statistically significantly ( Supplementary Fig. 4A and B) . Detailed results are presented in Supplementary Table 4 .
Discussion
A growing number of studies have consistently demonstrated that the presence of STAS in ADCs is associated with an increased risk for recurrence and a decreased rate of survival [5] [6] [7] [8] [9] [10] and thus have proposed STAS as a novel invasive pattern. 3, 4 In the present study, we explored the synergistic effect of STAS and tumor size on survival. The statistical analyses showed that STAS differentiates prognosis in patients with ADC 3 cm or smaller. Further analysis indicated that the unfavorable survival of patients with ADC 3 cm or smaller with STAS present was comparable to that of patients with larger tumors. In addition, in the subgroup analysis this trend was observed in tumors larger than 2 to 3 cm but not in tumors 2 cm or smaller. These data not only validate the invasive pattern of STAS but also provide preliminary evidence that STAS could be considered as a factor in the staging system to predict prognosis more precisely, especially in ADCs larger than 2 to 3 cm.
Kadota et al. first defined STAS and reported its clinical significance in lung ADCs in 2015. 5 Later studies have supported their conclusions. [6] [7] [8] [9] When the methods used by Kadota el al. were adopted to identify STAS in our study, the incidence of STAS was 32% in ADCs 2 cm or smaller, which was quite similar to that reported by other groups (35%-38% in those of the same tumor size). 5, 15 In addition, quite a few studies have reported that STAS was always identified simultaneously with the presence of other aggressive tumor behaviors, such as high-grade histologic patterns, visceral pleural invasion, and lymphovascular invasion. 5, 7 As was expected, our study revealed similar correlations. Specifically, STAS occurred less frequently in lepidic predominant ADC and more frequently in micropapillary and solid predominant ADC. More importantly, consistent with previous studies, 5-9 the present study, noted a significant negative impact of STAS on recurrence and survival after adjustment of these variables, which effectively proved that STAS is an independent risk pattern with clinical significance rather than an artifact. Finally, STAS was also characterized in other histologic types of lung cancer, and its malignant behavior remained. 6, 16 This evidence highlights the finding that STAS represents a novel invasive pattern; thus, it should be paid sufficient attention and recorded in pathologic reports.
The present study showed that the prognosis of patients with ADCs 3 cm or smaller and ADC larger than 2 to 3 cm was significantly stratified by STAS. In patients with tumors 2 cm or smaller, a similar trend could be observed in the both study and validation cohorts, although the difference did not reach statistical significance. Furthermore, at the recent 2016 World Conference on Lung Cancer, a study with a larger sample size that was conducted by Eguchi et al. revealed that the 5-year cumulative incidence of recurrence (CIR) and cumulative incidence of lung cancer-specific death (CID) in patients with ADCs 2 cm or smaller was stratified by STAS. 15 These results might suggest that STAS could be considered as a factor to upgrade T stage, which contributes to the accuracy of predicting the prognosis of early-stage ADCs. More importantly, the RFS and OS of patients with ADC larger than 2 to 3 cm with STAS were similar to those of patients with stage IB ADC. 17 Thus, patients with ADC larger than 2 to 3 cm with STAS might benefit from postoperative chemotherapy. 18, 19 However, future studies with large and well-characterized cohorts are warranted to validate this hypothesis.
In an initial report, STAS was identified as a risk factor in the prognosis of patients who underwent limited resection, but not those who underwent lobectomy. 5 In our study, 95% of patients underwent lobectomy, but the influence of STAS on recurrence and survival was still evident. One likely explanation for this disparity is the larger sample size in our study, with nearly 30% more cases than the earlier study. In Figure 3 . Recurrence-free survival and overall survival in patients with adenocarcinoma 2 cm or smaller (A are B) and larger than 2 to 3 cm (C and D) stratified by spread through air spaces (STAS) in the study cohort. HR, hazard ratio; CI, confidence interval.
addition, several subsequent studies also demonstrated the negative impact of STAS in patients who underwent lobectomy.
6,9,15 Eguchi et al. reported that in patients with ADC 2 cm or smaller with STAS who underwent lobectomy, the 5-year CIR and 5-year CID were much higher compared with those of patients without STAS (CIR ¼ 15.2% versus 7.8%; CID ¼ 7.2% versus 2.9%). 15 Shiono and Yanagawa also revealed that STAS is an independent risk factor for recurrence, even after excluding patients who underwent limited resection (data not shown but stated in the "Discussion" section of their report). 9 Moreover, central-type squamous cell carcinoma of the lung was more common and was not suitable for limited resection. However, Lu et al. presented evidence that STAS in lung squamous cell carcinomas has an adverse impact on patients' prognosis. 6 Taken together, these data collectively suggest that STAS is closely related to poor survival outcomes, independent of type of surgery.
It is a logical assumption that the distance between tumor surface and furthest STAS has extra significance related to surgical outcome. In the present study, we failed to identify more aggressive behavior of extensive STAS compared with limited STAS (less than or equal to three alveoli) (data not shown). Warth et al. reported that OS and disease-free survival are similar between extensive and limited STAS. 7 In another study by Lu et al. with fewer patients who underwent limited resection, the influence of extensive STAS on prognosis was comparable to that of limited STAS. 6 Thus, we speculated that extensive STAS might have an extra influence in patients who underwent limited resection rather than lobectomy. Some studies found that the increased risk for local recurrence in the same lobe or at the surgical margin after limited resection was closely correlated with STAS and might be a result of the furthest STAS. 5, 15 Thus, it is of utmost importance to detect the STAS pattern in surgical margins on frozen sections during limited pulmonary resection. Kameda et al. reported that STAS pattern could be identified in frozen sections with a satisfactory sensitivity, specificity, and accuracy of 71%, 92.4%, and 80%, respectively, 20 although these results should be further verified through prospective studies.
Some limitations of this study should be addressed. First, some potential biases were inevitable owing to its retrospective nature, such as selection bias and performance bias. Second, this clinical research was carried out in a single medical center. Therefore, a multicenter study in the future is warranted to verify our results. Third, we included ADCs 3 cm or smaller in this study; future studies are needed to cover the clinical significance of STAS in other histologic types of NSCLC and tumors of larger size (>3 cm) before STAS can be added to the staging system.
Conclusions
In summary, these results provide preliminary evidence that STAS could be considered as a factor in a staging system to predict the prognosis more precisely, especially in ADCs larger than 2 to 3 cm.
